GSK, Novartis to close vax deal next week; NICE rejects Dendreon's Provenge;

> GlaxoSmithKline ($GSK) and Novartis ($NVS) are preparing to close their multi-billion-dollar asset swap--which will send most of Novartis' vaccines unit to Glaxo--in the week beginning March 2. Report

> The U.K.'s cost watchdogs have shot down Dendreon's ($DNDN) Provenge, the price is "too high for the benefit it may provide to patients." Report

> Protein Sciences has added Cardinal Health ($CAH) and McKesson ($MCK) as distributors for its flu vaccine, Flublok. Release

> Maryland's Sanaria is leveraging a logistics partnership with Cryoport to support its malaria vaccine development. More

> A centralized statewide reminder system for immunizations may be a more reliable way to increase overall vaccination rates, a new report says. More

And Finally... Pro-vaccine Facebook ($FB) founder Mark Zuckerberg is urging Facebook users to read a book about why people fear vaccination. More

Suggested Articles

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.

CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.